Primary regulatory

Sirolimus/Rapamune for lymphangioleiomyomatosis.

U.S. Food and Drug Administration, Orphan Drug Designations and Approvals. Sirolimus/Rapamune for lymphangioleiomyomatosis. Marketing approval 2015-05-28.

U.S. Food and Drug AdministrationPublished 2015-05-28Accessed 2026-07-12

Open original source

Registry record

Source metadata

Publisher: U.S. Food and Drug Administration
Source type: Primary regulatory
Registry ID: research-rapa-03
Source code: RAPA-03

Source usage

Linked from 1 page

Compound

Rapamycin (sirolimus)

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.